Amarin Corporation PLC (AMRN) Announces Notification of Patent Allowance for U.S. Application 13/417,899 Related to Combination Product of Vascepa® and Statin Therapy
5/22/2013 9:50:18 AM
More...
|
Amarin Corporation PLC (AMRN) Reports First Quarter 2013 Financial Results and Provides Update on Operations
5/10/2013 9:31:38 AM
More...
|
Amarin Corporation PLC (AMRN) Announces FDA Acceptance of Supplemental New Drug Application (sNDA) for Vascepa(R) for the Treatment of Patients With High Triglycerides (>200 mg/dL and <500 mg/dL) With Mixed Dyslipidemia
4/23/2013 11:52:14 AM
More...
|
Amarin Corporation PLC (AMRN) Announces Approval of Supplemental New Drug Application for Chemport as Additional Vascepa® Active Pharmaceutical Ingredient Supplier
4/18/2013 11:34:44 AM
More...
|
Amarin Corporation PLC (AMRN) Announces New Clinical Data Showing Significant Reductions in Apolipoprotein C-III Levels in MARINE and ANCHOR Studies of Vascepa®
4/8/2013 11:28:55 AM
More...
|
Amarin Corporation PLC (AMRN) Announces Notification of Patent Allowance for U.S. Application 13/614,111 Related to Vascepa® and Planned ANCHOR Indication
3/7/2013 11:35:45 AM
More...
|
Amarin Corporation PLC (AMRN) Announces Submission of Supplemental New Drug Application (sNDA) for Vascepa® for the Treatment of Patients With High Triglycerides With Mixed Dyslipidemia
2/26/2013 11:23:26 AM
More...
|
Amarin Corporation PLC (AMRN) Announces Notification of Additional U.S. Patent Allowance for U.S. Application 13/272,520 Based on ANCHOR Clinical Trial Results
2/1/2013 8:54:11 AM
More...
|
Amarin Corporation PLC (AMRN) Announces Notification of Two Additional Patent Allowances for U.S. Applications (13/458,496 and 13/349,157) Related to Vascepa® and FDA Approved MARINE Indication
1/31/2013 9:40:28 AM
More...
|
Amarin Corporation PLC (AMRN) Announces First Notification of U.S. Patent Allowance Based on ANCHOR Clinical Trial Results
1/24/2013 9:31:13 AM
More...
|
|